There is no single “best” weight-loss medication for everyone. The right treatment depends on your medical history, weight-related conditions, previous treatment, medication preferences, side-effect risks, insurance coverage, and personal goals.
The purpose of this page
Use this guide to understand the major differences between treatment options. It is not a medication selector or a substitute for a medical evaluation.
| Option | Type | How Taken | Frequency | Recognizable Names | Key Consideration |
|---|---|---|---|---|---|
| Semaglutide | GLP1 | Injection or tablet | Weekly injection / daily tablet | Wegovy® / Ozempic® | Wegovy is the semaglutide product with weight-management indications; brand indications differ. |
| Tirzepatide | GIP/GLP1 | Injection | Weekly | Zepbound® / Mounjaro® | Zepbound includes chronic weight-management and obesity-related sleep-apnea indications. |
| Orforglipron | GLP1 | Tablet | Daily | Foundayo® | An oral GLP1 option; a different active medication from semaglutide. |
| Oral semaglutide | GLP1 | Tablet | Daily | Wegovy® tablets / Rybelsus® | Both contain semaglutide, but product indications and dosing instructions differ. |
| Naltrexone / bupropion | Non-GLP1 | Tablet | Daily regimen | Contrave® | Important considerations include blood pressure, seizure risk, mood, drug interactions, and opioid use. |
| Liraglutide | GLP1 | Injection | Daily | Saxenda® | An established daily injectable GLP1 option; newer therapies are now often used more frequently. |
Weekly injectable therapies can be convenient for patients who prefer not to take a medication every day. Semaglutide injection and tirzepatide are well-known examples. They differ in mechanism, FDA-approved indications, expected effects, side-effect profiles, and insurance coverage.
Oral treatment may appeal to patients who prefer tablets or are uncomfortable with injections. Options include oral GLP1 therapies such as Wegovy tablets and Foundayo, as well as non-GLP1 treatment such as Contrave. Oral medications still require careful selection, correct administration, and follow-up.
Saxenda is a daily injectable GLP1 medication. Although newer medications are commonly discussed today, Saxenda remains an FDA-approved option for selected patients.
GLP1 receptor agonists act on pathways involved in appetite, fullness, food intake, glucose regulation, and metabolism. Examples in this section include semaglutide, orforglipron, and liraglutide.
Tirzepatide acts on both GIP and GLP1 receptor pathways. It is available under different brand names with different FDA-approved indications.
Contrave combines naltrexone and bupropion and works through central nervous system pathways involved in appetite and reward. It provides a different mechanism for selected patients.
A medication that is appropriate for one person may be inappropriate for another. Your physician may consider factors such as:
Every prescription weight-management medication can cause side effects. GLP1 and GIP/GLP1 medications commonly cause gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, or abdominal discomfort, particularly during dose escalation.
Contrave has a different safety profile, including important considerations involving blood pressure, seizure risk, mood, medication interactions, and opioid use. The purpose of the consultation is to balance potential benefit against individual risk rather than choosing a medication solely because it is popular.
No.
Average clinical-trial weight loss is useful information, but it is only one part of medication selection. A treatment is not helpful if it is contraindicated, poorly tolerated, inaccessible, not covered, or difficult for the patient to continue.
❇︎ The most appropriate medication is one that offers a favorable balance of effectiveness, safety, tolerability, accessibility, and long-term sustainability for the individual patient.
Insurance coverage for obesity medications varies significantly. Some plans cover multiple options, some require prior authorization, some prefer one medication over another, and some exclude anti-obesity medications.
A patient may arrive asking for a specific medication and discover that another evidence-based option is better covered. When appropriate, our team can help address prior-authorization requirements and discuss alternatives if coverage is denied.
Important
Insurance coverage does not determine whether a medication is medically appropriate. Medical appropriateness comes first; coverage and access are then considered as part of the treatment plan.
That is completely reasonable. Many patients come to their visit asking about Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo, Rybelsus, Contrave, or another medication they have heard about.
Your physician can discuss that specific medication with you, explain its approved uses, benefits, risks, alternatives, and insurance considerations, and determine whether it fits your medical needs.
Prescription obesity medication may be considered for selected patients with weight recurrence or inadequate weight loss after bariatric surgery. Medication selection should account for the type of prior surgery, gastrointestinal anatomy, nutritional status, reflux or other symptoms, and the patient’s overall medical history.
Review weight history, medical conditions, previous treatment, medications, and goals.
Injection vs. tablet, treatment frequency, concerns, prior experiences, and expectations.
Identify contraindications, interactions, and monitoring needs.
Review insurance coverage and prior-authorization requirements when appropriate.
Begin treatment when appropriate, assess response and side effects, and adjust the plan over time.
Average results differ among medications and trials, but individual response varies. Treatment choice should not be based on one number alone.
Not necessarily. Both oral and injectable treatments can be effective. The better option depends on your medical needs, preferences, tolerability, administration requirements, and coverage.
Sometimes. A change may be appropriate because of effectiveness, side effects, medical considerations, access, or insurance coverage. Switching should be directed by your clinician.
Combination therapy is not appropriate for everyone, and some combinations should not be used. Any combination requires individualized medical judgment and review of current evidence and labeling.
Coverage matters, but medical appropriateness comes first. Your physician can help identify appropriate options and then consider coverage and authorization requirements.
This program is designed around FDA-approved prescription treatment options. Treatment is selected after medical evaluation.
Medical weight management can still address nutrition, activity, sleep, behavioral factors, metabolic health, and other treatment strategies. Medication is one tool, not the entire program.
You do not need to choose a medication before your appointment. Start with a physician-led telemedicine evaluation, and we can review your health, preferences, treatment options, safety considerations, and insurance coverage together.
This page is for general educational purposes and does not replace individualized medical advice. Prescription medications have potential benefits, side effects, contraindications, warnings, and drug interactions. Treatment decisions are made after an appropriate medical evaluation. FDA labeling, medication availability, and insurance coverage may change.
